DOCSLIB.ORG

Small Airways Dysfunction in Asthma: Evaluation and Management to Improve Asthma Control Omar S Usmani*

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Small Airways Dysfunction in Asthma: Evaluation and Management to Improve Asthma Control Omar S Usmani* Review Allergy Asthma Immunol Res. 2014 September;6(5):376-388. http://dx.doi.org/10.4168/aair.2014.6.5.376 pISSN 2092-7355 • eISSN 2092-7363 Small Airways Dysfunction in Asthma: Evaluation and Management to Improve Asthma Control Omar S Usmani* Airway Disease Section, National Heart and Lung Institute, Imperial College London & Royal Brompton Hospital, London, UK This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The small airways have been neglected for many years, but interest in the topic has been rekindled with recent advances in measurement tech- niques to assess this region and also the ability to deliver therapeutics to the distal airways. Current levels of disease control in asthmatic patients remain poor and there are several contributory factors including; poor treatment compliance, heterogeneity of asthma phenotypes and associated comorbidities. However, the proposition that we may not be targeting all the inflammation that is present throughout the whole respiratory tree may also be an important factor. Indeed decades ago, pathologists and physiologists clearly identified the importance of small airways dysfunction in asthmatic patients. With improved inhaler technology to deliver drug to target the whole respiratory tree and more sensitive measures to assess the distal airways, we should certainly give greater consideration to treating the small airway region when seeing our asthmatic patients in clinic. The aim of this review is to address the relevance of small airways dysfunction in the daily clinical management of patients with asthma. In particular the role of small particle aerosols in the management of patients with asthma will be explored. Key Words: Small airways; asthma; physiology; pharmacology; inhalation; aerosols; corticosteroids; long-acting beta agonists INTRODUCTION have been many terms used to describe these aerosols, for the purposes of this review small particle aerosols are defined as There have been many reviews published recently in the last those ≤2 microns in diameter. The manuscript was a review of few years on small airways dysfunction and its importance in the literature using keywords of small airways; asthma; physiol- respiratory disease, particularly in asthma, as interest in this ogy; pharmacology; inhalation; aerosols; corticosteroids; long- topic has be rekindled by advances in measurement tech- acting beta agonists; medication. niques of, and therapeutic delivery to, the peripheral lung re- gions.1-4 This review attempts to approach the topic in a differ- Asthma control is still not optimal ent manner. It will address the significance of small airways The last three decades have seen important advances in the dysfunction in the daily clinical management of patients with management of patients with asthma and these include; great- asthma and in particular, the literature will be reviewed to help er awareness and timely diagnosis of the disease, pharmaco- answer the following pragmatic questions to inform the busy logical interventions principally targeted at controlling the un- practicing respiratory healthcare professional in clinic. derlying airways inflammation, the realisation of and appropri- ate management of the significant comorbidities associated 1. Is small airways dysfunction relevant in the asthmatic pa- with the condition, and a multidisciplinary approach to care for tient? 2. If so, how can we target drug to treat small airways dysfunc- tion? Correspondence to: Omar S Usmani, MD, PhD, Airway Disease Section, Guy 3. Does treatment of the small airways make a difference to Scadding Building, National Heart & Lung Institute, Imperial College London & Royal Brompton Hospital, Dovehouse Street, London, SW3 6LY, UK. the patient and specifically, to asthma control? Tel: +44 (0)207 351 8051; Fax: +44 (0)207 351 8937; 4. If so, do doctors need to treat small airways dysfunction? E-mail: [email protected] In particular the role of small particle aerosols in the manage- Received: February 25, 2014; Accepted: April 01, 2014 ment of patients with asthma will be explored, and as there •There are no financial or other issues that might lead to conflict of interest. 376 http://e-aair.org © Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease AAIR Small Airways Dysfunction in Asthma this chronic disease in the community. However, despite these less than 15% of patients persist with inhaled therapy in the significant advances, the present day control of disease in pa- course of a year.13 These data highlight that despite current ther- tients with asthma remains rather unsatisfactory. apeutic strategies, there remains a great unmet need in the In an European cross-sectional survey, Demoly and col- management of asthmatic patients with mild, moderate and leagues assessed the levels of patient-reported asthma control severe disease. on the health status of patients and their use of healthcare re- sources (visits to their doctor, emergency room attendance, and Small airways phenotype admission to hospital) over a five year period from 2006 to Asthma is now being recognized as a complex clinical syn- 2010.5 The authors observed that despite ongoing treatment, drome, rather than a specific disease entity, and as an ‘umbrella’ more than 50% of all asthmatic patients were still characterized term encompassing a heterogeneous group of phenotypes and as being not well controlled (54% in 2010, 57% in 2008, and 55% endotypes that may have different treatment responses.14,15 In in 2006). The authors also noted that worsening asthma control light of this understanding, the approach of ‘one treatment to fit was associated with significantly greater healthcare resource all’ may not be appropriate, and there is a move towards person- utilisation in the preceding six months of assessment. Similar alising asthma therapy based on specific phenotypes.16 So, could findings have also been reported in the Asia Pacific region by it be that asthmatic patients who continue to experience poor Lai and colleagues, where daytime asthma symptoms were re- disease control and frequent exacerbations exhibit persistent ported by 51% of asthmatic patients and only 34% of patients airways inflammation that is not being addressed by existing an- with severe persistent asthma felt their disease was well or ti-inflammatory treatments? More specifically, a key contributo- completely controlled.6 Certainly, the compliance of patients ry factor to poor disease control might be that such patients ex- with their prescribed medication and also the correct use of in- press a ‘small airways phenotype’, where there is ongoing and haled respiratory medicines are important concerns and repre- unopposed small airways inflammation and dysfunction that is sent significant factors contributing to reported studies on poor not being targeted or controlled by current therapies; that is, the asthma control.7 The management of patients with asthma has inability of the inhaler devices that are routinely being used in been improved with the advent of combination treatment of in- clinical practice to effectively deliver and deposit their aero- haled corticosteroids (ICS) with long-acting beta-agonist solised medicine to treat the small airway region of the lung.17 (LABA), where combination therapy has clearly been shown Historically, the small airways are defined as airways with an clinically to improve disease control through mechanisms that internal diameter of less than 2 mm.18,19 Weibel’s seminal work modulate the underlying airways inflammation.8,9 Yet studies on the quantitative study of lung anatomy helps us to acknowl- have shown that asthmatic patients are still not optimally con- edge there are three main lung regions to appreciate when con- trolled with such management. sidering airway disease and targeted treatment; the large (>2 In a post hoc analysis of data from the Formoterol and Corti- mm) conducting airway zone which comprises airway genera- costeroid Establishing Therapy (FACET) study,10 O’Byrne and tions 1-7; the small (<2 mm) conducting airway zone, which colleagues reported that the addition of the LABA, formoterol, comprises airway generations 8-16; and the small (<2 mm) re- to the ICS, budesonide, led to a greater probability of well-con- spiratory acinar zone, which comprises airway generations 17- trolled asthma compared to an increased dose of budesonide, 23.20 It is well established that inflammation in asthma involves where treatments were given for one year.11 However, their data the large airways, but histopathological evidence from several showed that nearly 40% of patients on the combination of for- studies have clearly shown that the inflammation in asthmatic moterol 24 µg/budesonide 800 µg daily, did not achieve sus- subjects also involves the small airways; that is, the complete tained well-controlled asthma in the last two months of treat- airway tree.21,22 It is also now recognised that the small airways ment; that is, the patients were characterised as being poorly are the major site of airflow limitation in both asthma and controlled or with intermediate controlled asthma. Indeed, of chronic obstructive pulmonary disease,23,24 yet they are known those patients
Load more

Recommended publications
  • Air Trapping on Computed Tomography: Regional Versus Diffuse
    EDITORIAL | SMOKING Air trapping on computed tomography: regional versus diffuse Firdaus A. Mohamed Hoesein and Pim A. de Jong Affiliation: Dept of Radiology, University Medical Center Utrecht, Utrecht, The Netherlands. Correspondence: Firdaus A. Mohamed Hoesein, University Medical Center Utrecht, Department of Radiology, Heidelberglaan 100, PO box 855000, 3508 GA, Utrecht, The Netherlands. E-mail: [email protected] @ERSpublications Future studies on the distribution of air trapping in the lungs of COPD patients are needed http://ow.ly/86hc304JiIK Cite this article as: Mohamed Hoesein FA, de Jong PA. Air trapping on computed tomography: regional versus diffuse. Eur Respir J 2017; 49: 1601791 [https://doi.org/10.1183/13993003.01791-2016]. Chronic obstructive pulmonary disease (COPD) is diagnosed and classified by spirometry, assessing the presence of airflow obstruction and extent of forced expiratory flow deterioration. Spirometry, however, is unsuitable for characterising and quantifying the underlying pulmonary pathology of COPD, including alveolar destruction (emphysema) and airway remodelling (large- and small-airway disease). Accurate diagnosis of the pulmonary pathologies underlying COPD is seen as an important step towards better understanding its biology and “personalised” treatment. Computed tomography (CT) of the lungs provides an excellent opportunity to assess COPD in vivo and quantify its macroscopic pathology [1–3]. Emphysema and airway remodelling can be visually assessed and automatically quantified, and several studies have shown associations with morbidity and mortality [4–7]. In addition, CT can provide information on the spatial distribution of disease. In this issue of the European Respiratory Journal,KARIMI et al. [8] hypothesise that regional air trapping maybe a new imaging marker, in addition to emphysema, large-airway remodelling and diffuse air trapping.
    [Show full text]
  • Imaging of Small Airways Disease
    SYMPOSIA Imaging of Small Airways Disease Gerald F. Abbott, MD,* Melissa L. Rosado-de-Christenson, MD,w zy Santiago E. Rossi, MD,J and Saul Suster, MDz SECONDARY PULMONARY LOBULE Abstract: Small airways disease includes a spectrum of inflammatory The secondary pulmonary lobule (SPL) is a key and fibrotic pulmonary diseases centered on the small conducting structure in the lung anatomy and is distinguished as the airways. High-resolution computed tomography plays a key role in the detection and classification of small airways disease and, when smallest functioning subunit of lung that is bound by combined with relevant clinical and pathologic findings, leads to a connective tissue septa, supplied by a lobular bronchiole more accurate diagnosis. The imaging manifestations of small airways and arteriole, and drained by veins and lymphatics in the disease on high-resolution computed tomography may be direct or interlobular septa. Each SPL measures 1 to 2.5 cm and indirect signs of small airway involvement and include centrilobular contains 3 to 12 acini. The SPL are better formed and more nodules and branching nodular (tree-in-bud) opacities, or the easily recognized in the peripheral subpleural lung and demonstration of mosaic attenuation that is typically exaggerated on are smaller and less regular in the central lung. The SPL are expiratory computed tomography. This article reviews the normal not normally visible on radiography or computed tomo- anatomy and histology of bronchioles and the clinical, pathologic, and graphy (CT)/HRCT (Fig. 1).
    [Show full text]
  • Residual Volume and Total Lung Capacity to Assess Reversibility in Obstructive Lung Disease
    Residual Volume and Total Lung Capacity to Assess Reversibility in Obstructive Lung Disease Conor T McCartney MD, Melissa N Weis MD, Gregg L Ruppel MEd RRT RPFT FAARC, and Ravi P Nayak MD BACKGROUND: Reversibility of obstructive lung disease is traditionally defined by changes in FEV1 or FVC in response to bronchodilators. These may not fully reflect changes due to a reduction in hyperinflation or air-trapping, which have important clinical implications. To date, only a handful of studies have examined bronchodilators’ effect on lung volumes. The authors sought to better characterize the response of residual volume and total lung capacity to bronchodilators. METHODS: Responsiveness of residual volume and total lung capacity to bronchodilators was assessed with a retrospective analysis of pulmonary function tests of 965 subjects with obstructive lung disease as defined by the lower limit of normal based on National Health and Nutritional Examination Survey III prediction equations. RESULTS: A statistically significant number of subjects demonstrated response to bronchodilators in their residual volume independent of re- sponse defined by FEV1 or FVC, the American Thoracic Society and European Respiratory Society criteria. Reduced residual volume weakly correlated with response to FEV1 and to FVC. No statistically significant correlation was found between total lung capacity and either FEV1 or FVC. CONCLUSIONS: A significant number of subjects classified as being nonresponsive based on spirometry have reversible residual volumes. Subjects whose residual volumes improve in response to bronchodilators represent an important subgroup of those with obstructive lung disease. The identification of this subgroup better characterizes the heterogeneity of obstructive lung disease. The clinical importance of these findings is unclear but warrants further study.
    [Show full text]
  • PFT Interpretation
    PFT Interpretation Presented by: Shazhad Manawar, MD Medical Director Respiratory Care & Pulmonary Rehab McLaren Bay Region Introduction History or symptoms suggestive of lung disease. Risk factors for lung disease are present. Pulmonary Function Tests Spirometry Spirometry before and after bronchodilator Lung volumes Diffusing capacity for carbon monoxide Maximal respiratory pressures Flow volume loops Spirometry Volume of air exhaled at specific time points during forceful and complete exhalation. Total exhaled volume, know as the FVC (forced vital capacity). Volume exhaled in the first second, know as the forced expiratory volume in one second (FEV1) Spirometry - continued Ratio (FEV1/FVC) are the most important variables Minimal risk Key diagnostic test Asthma Chronic Obstructive Pulmonary Disease (COPD) Chronic cough Spirometry - continued Monitor a broad spectrum of respiratory diseases. Asthma COPD Interstitial Lung Disease Neuromuscular diseases affecting respiratory muscles Spirometry - continued Slow vital capacity (SVC) Useful measurement when FVC is reduced and airway obstruction is present Post-bronchodilator Determine the degree of reversibility Administration of albuterol Technique is important Increase in the FEV1 of more than 12% or greater than 0.2 L suggests acute bronchodilator responsiveness. Subjective improvements Post-bronchodilator - continued Thus, the lack of an acute bronchodilator response on spirometry should not preclude a one to eight week therapeutic trial of bronchodilators
    [Show full text]
  • Demystifying Fibrotic Hypersensitivity Pneumonitis Diagnosis: It’S All About Shades of Grey
    EDITORIAL | INTERSTITIAL LUNG DISEASE Demystifying fibrotic hypersensitivity pneumonitis diagnosis: it’s all about shades of grey Simon L.F. Walsh1 and Luca Richeldi2 Affiliations: 1National Heart and Lung Institute, Imperial College, London, UK. 2Fondazione Policlinico A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy. Correspondence: Simon L.F. Walsh, National Heart and Lung Institute, Imperial College, London SW3 6LY, UK. E-mail: [email protected] @ERSpublications The headcheese pattern which describes a form of mosaic attenuation which combines areas of ground-glass opacification, lobular areas of low attenuation and normal lung is highly specific for a diagnosis of fibrotic hypersensitivity pneumonitis http://bit.ly/2WO2mn7 Cite this article as: Walsh SLF, Richeldi L. Demystifying fibrotic hypersensitivity pneumonitis diagnosis: it’s all about shades of grey. Eur Respir J 2019; 54: 1900906 [https://doi.org/10.1183/13993003.00906-2019]. The spotlight on diagnosis in hypersensitivity pneumonitis (HP) intensifies. Over the past 18 months we have seen two pulmonary perspectives proposing diagnostic approaches to HP; an international Delphi survey and several imaging studies focused on clinical and imaging features predictive of HP; and clinical practice guideline initiatives for HP, sponsored by the American Thoracic Society and American College of Chest Physicians, are underway [1–5]. Despite this growing literature, HP continues to resist our best attempts to develop an accurate, reproducible case definition for this disorder. Making a diagnosis of HP is challenging because it is often shadowed by marginal exposure histories, borderline antigen positivity or discordant imaging patterns, and treatment decisions are often based on diagnostic probability rather than certainty [4, 5].
    [Show full text]
  • Differences in Regional Air Trapping in Current Smokers with Normal Spirometry
    ORIGINAL ARTICLE SMOKING Differences in regional air trapping in current smokers with normal spirometry Reza Karimi1,3, Göran Tornling 1, Helena Forsslund1, Mikael Mikko1, Åsa M. Wheelock1, Sven Nyrén2,3 and C. Magnus Sköld1,3 Affiliations: 1Dept of Medicine and Centre for Molecular Medicine (CMM) Respiratory Medicine Unit, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden. 2Dept of Molecular Medicine and Surgery, Division of Radiology, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden. 3These authors contributed equally. Correspondence: Reza Karimi, Dept of Medicine Solna, Karolinska Institutet, Lung-Allergy Clinic N2:02, Karolinska University Hospital Solna, SE 171 76 Stockholm, Sweden. E-mail: [email protected] @ERSpublications Smokers with regional air trapping on expiratory CT scan are less obstructive/have less emphysema than those without http://ow.ly/96lV305tgtZ Cite this article as: Karimi R, Tornling G, Forsslund H, et al. Differences in regional air trapping in current smokers with normal spirometry. Eur Respir J 2017; 49: 1600345 [https://doi.org/10.1183/13993003.00345- 2016]. ABSTRACT We investigated regional air trapping on computed tomography in current smokers with normal spirometry. It was hypothesised that presence of regional air trapping may indicate a specific manifestation of smoking-related changes. 40 current smokers, 40 patients with chronic obstructive pulmonary disease (COPD), and 40 healthy never- smokers underwent computed tomography scans. Regional air trapping was assessed on end- expiratory scans and emphysema, micronodules and bronchial wall thickening on inspiratory scans. The ratio of expiratory and inspiratory mean lung attenuation (E/I) was calculated as a measure of static (fixed) air trapping. Regional air trapping was present in 63% of current smokers, in 45% of never smokers and in 8% of COPD patients (p<0.001).
    [Show full text]
  • Obliterative Bronchiolitis
    13 Obliterative Bronchiolitis C. Isabela S. Silva and Nestor L. Müller Summary Obliterative bronchiolitis (OB) is a condition characterized by inflammation and fibrosis of the bronchiolar walls resulting in narrowing or obliteration of the bronchiolar lumen. The most common causes are childhood lower respiratory tract infection, hematopoietic stem cell or lung and heart-lung transplantation, and toxic fume inhalation. The most frequent clinical manifestations are progressive dyspnea and dry cough. Pulmonary function tests demonstrate airflow obstruction and air trapping. Radiographic manifestations include reduction of the peripheral vascular markings, increased lung lucency, and overinflation. The chest radiograph, however, is often normal. High-resolution CT is currently the imaging modality of choice in the assessment of patients with suspected or proven OB. The characteristic findings on high-resolution CT consist of areas of decreased attenuation and vascularity (mosaic perfusion pattern) on inspiratory scans and air trapping on expiratory scans. Other CT findings of OB include bronchiectasis and bronchiolectasis, bronchial wall thickening, small centrilobular nodules, and three-in-bud opacities. Recent studies suggest that hyperpolarized 3He-enhanced magnetic resonance imaging may allow earlier recognition of obstructive airway disease and therefore may be useful in the diagnosis and follow-up of patients with OB. Key Words: Bronchiolitis; bronchiolitis obliterans; bronchiolitis obliterans syndrome; constrictive bronchiolitis; computed tomography; obliterative bronchiolitis; small airways disease. 1. INTRODUCTION Bronchiolitis is a generic term applied to various inflammatory and fibrosing diseases that affect the small airways, which by definition are airways that measure less than 2 mm in diameter (i.e., primarily membranous and respiratory bronchioles) (1,2). Bronchiolitis is common and occurs in various clinical settings (1–5).
    [Show full text]
  • Pulmonary Function Tests – a Refresher
    PULMONARY FUNCTION TESTS – A REFRESHER Khizer Hayat Khan M Rahim Khan York Teaching Hospital INTRODUCTION • Pulmonary function tests (PFTs) are non-invasive tests that show how well the lungs are working. • The tests measure lung volume, capacity, rates of flow, and gas exchange PURPOSE OF PFTs • Diagnosis of symptomatic disease • Screening of early asymptomatic disease • Monitoring response to treatment • Prognostication of known disease TYPES OF PFTs Spirometry STANDARD PFTs Lung volumes Gas transfer Exercise oximetry SPECIALIZED PFTs 6 minute walk test Peak flow CATEGORIES OF LUNG DISEASES • PFTs help classify disease in following categories: • OBSTRUCITVE | This is when air has trouble flowing out of the lungs due to airway resistance. This causes a decreased flow of air • RESTRICTIVE | This is when the lung tissue and/or chest muscles can’t expand enough • PULMONARY VASCULAR DISEASES | SPIROMETRY VALIDITY OF PFTs • Evaluate acceptability & reproducibility • Acceptability • Good effort – a rapid increase in airflow at the start of exhalation • Complete maneuver – at least 6s of exhalation ending up in plateau in flow • Reproducibility • All 3 FEV1 within 200ml of each other • All 3 FVC within 200ml of each other LUNG VOLUMES LUNG VOLUMES VOLUME AGAINST TIME FLOW VOLUME LOOP SPIROMETRY PATTERNS • Normal • Obstructive • Restrictive • Mixed • Fixed upper airway obstruction • Variable intra thoracic upper airway obstruction • Variable extra thoracic upper airway obstruction OBSTRUCTIVE SPIROMETRY • FEV1:FVC ratio <70% • FEV1 falls disproportionately
    [Show full text]
  • Recognizing Interstitial Lung Disease
    Recognizing Interstitial Lung DIsease Douglas Arenberg, M.D. University of Michigan Health System Division of Pulmonary/Critical Care Medicine No relevant disclosures Session Objectives By the end of this session, participants will be able to… • Recognize clinical scenarios where interstitial lung disease is to be suspected and the key clinical/radiographic findings in patients with the most common form(s) of interstitial lung disease • Understand the general diagnostic pathway patients with suspected interstitial lung disease • Discuss the potential benefits and adverse reactions of approved therapies for IPF • Outline – When to suspect interstitial lung disease – Tools for diagnosis (History, Spirometry, HRCT, Biopsy) IPF Prevalence among those with dyspnea COPD: chronic obstructive pulmonary disease; IPF: idiopathic pulmonary fibrosis. 1. Raghu G et al. Resp Crit Care Med. 2006;174:810-816. 2. Go AS et al. Circulation. 2013;127:e6-e245. 3. Wheaton AG et al. MMWR Morb Mortal Wkly Rep. 2015;64:289-295. Interstitial Lung Diseases - Difficulties • Diverse group of disorders (130+) • Similar symptoms, physiology, radiology • Difficult nomenclature • Limited, often toxic, treatments Diffuse Parenchymal Lung Disease (DPLD) DPLD of known cause, eg, Idiopathic Granulomatous Other forms of drugs or association, eg, Interstitial DPLD, eg, DPLD, eg, LAM, HX, collagen vascular disease Pneumonias sarcoidosis etc Major Rare Unclassifiable Idiopathic Pulmonary Fibrosis Lymphoid Interstitial Pneumonia Nonspecific interstitial pneumonia (idiopathic)
    [Show full text]
  • Interpretation of Pulmonary Function Tests (Pfts)
    INTERPRETATION OF PULMONARY FUNCTION TESTS (PFTS) Anna Neumeier, MD Assistant Professor, Department of Pulmonary Sciences and Critical Care Medicine ACP February 2020 LEARNING OBJECTIVES 1. Describe the clinical indications for pulmonary function testing 2. Understand the physiology of the core pulmonary function tests: spirometry, lung volumes and DLCO 3. Apply an organized approach to interpreting pulmonary function tests 4. Identify obstructive, restrictive, mixed obstructive-restrictive and pulmonary vascular patterns of abnormalities on pulmonary function testing. INDICATIONS FOR PFTS • Evaluation of patients presenting with dyspnea • Evaluating disease severity and monitoring response to treatment • Determine fitness for surgery • *thoracic surgery/lung resection PFTS: AVAILABLE MEASURES • Spirometry • Airflow (how much air, how fast) • (Static) Lung volumes • Volume (how much air) • Diffusing Capacity/DLCO • Gas exchange (how effective) • Other testing: • Airway responsiveness • Respiratory muscle strength testing • Compliance of the lungs A PHYSIOLOGY REFRESHER: LUNG VOLUMES AND CAPACITIES Al-Askhar. Cleveland Clinic Journal of Medicine. 2003 Al-Askhar. Cleveland Clinic Journal of Medicine. 2003 AN APPROACH TO PFT INTERPRETATION STEP 1: CONFIRM PATIENT DEMOGRAPHIC DATA DEFINING NORMAL AND ABNORMAL VALUES • Interpretation involves comparison of the patient’s values with reference values (Crapo Hsu, NHANES III, GLI) • Dependent on age, sex, race and ethnicity, height • African Americans have values that are 12% lower than Caucasians
    [Show full text]
  • What Is the Clinical Value of Lung Volumes?
    What Is the Clinical Value of Lung Volumes? Gregg L Ruppel MEd RRT RPFT FAARC Introduction Is a Low TLC (ie, Restriction) a Useful Measurement? Do Lung Volumes Tell Us Anything Meaningful About Obstruction? Does It Make Any Difference How You Measure Lung Volumes? Summary Lung volumes are considered part of a complete pulmonary function test, but their value for enhancing clinical decision making is unknown. Unlike spirometry and diffusing capacity of the lung for carbon monoxide (DLCO), which do contribute to confirming or excluding a diagnosis, there are few clear indications when lung volumes are discriminatory. Confirming “restriction” when vital capacity (VC) or FVC is reduced is perhaps the most important. A restrictive pattern can have many etiologies, and clinicians often use VC or FVC as a primary index of lung volume. This makes “physiologic” sense because, in healthy subjects, and in patients with true restriction, VC comprises most of the total lung capacity (TLC). Mixed obstruction-restriction and the nonspecific pattern (ie, reduced FVC and FEV1, normal FEV1/FVC and TLC) require measuring TLC to confirm the underlying physiology. In obesity, VC and TLC may remain within normal limits, but functional residual capacity (FRC) can exponentially decrease. Increased lung volumes, particularly residual volume (RV), are commonly observed in airway obstruction. TLC may be normal, but is frequently increased in the late stages of COPD. Hyperinflation and air-trapping are terms commonly used to reflect these changes, but are not well standardized. The variability of lung volumes related to degree of obstruction suggests that measuring gas-trapping may be needed to monitor therapy.
    [Show full text]
  • Air Trapping in Usual Interstitial Pneumonia Pattern at CT
    www.nature.com/scientificreports OPEN Air trapping in usual interstitial pneumonia pattern at CT: prevalence and prognosis Received: 16 July 2018 Bruno Hochhegger 1,2,3, Felipe Duenhas Sanches1,2, Stephan Philip Leonhardt Altmayer2,3, Accepted: 11 October 2018 Gabriel Sartori Pacini 2,3, Matheus Zanon 2,3, Álvaro da Costa Batista Guedes3, Published: xx xx xxxx Guilherme Watte2, Gustavo Meirelles4, Marcelo Cardoso Barros5, Edson Marchiori6 & Adalberto Sperb Rubin2,3 This study was conducted to evaluate the presence of air trapping in patients with idiopathic pulmonary fbrosis (IPF) and other interstitial lung diseases (ILDs) (non-IPF), showing the radiological pattern of usual interstitial pneumonia (UIP). Retrospectively, we included 69 consecutive patients showing the typical UIP pattern on computed tomography (CT), and 15 fnal diagnosis of IPF with CT pattern “inconsistent with UIP” due to extensive air trapping. Air trapping at CT was assessed qualitatively by visual analysis and quantitatively by automated-software. In the quantitative analysis, signifcant air trapping was defned as >6% of voxels with attenuation between −950 to −856 HU on expiratory CT (expiratory air trapping index [ATIexp]) or an expiratory to inspiratory (E/I) ratio of mean lung density >0.87. The sample comprised 51 (60.7%) cases of IPF and 33 (39.3%) cases of non-IPF ILD. Most patients did not have air trapping (E/I ratio ≤0.87, n = 53, [63.1%]; ATIexp ≤6%, n = 45, [53.6%]). Air trapping in the upper lobes was the only variable distinguishing IPF from non-IPF ILD (prevalence, 3.9% vs 33.3%, p < 0.001). In conclusion, air trapping is common in patients with ILDs showing a UIP pattern on CT, as determined by qualitative and quantitative evaluation, and should not be considered to be inconsistent with UIP.
    [Show full text]